Description
Tissue-Selective Precision
S-23 represents a distinct evolution in selective androgen receptor modulation—engineered by GTx Inc. for precise anabolic targeting without the traditional androgenic burden.
The Mechanism
Unlike conventional androgens, S-23 demonstrates differential tissue selectivity through unique co-regulator recruitment patterns. Its molecular structure effectively limits activation in reproductive tissues while maintaining full agonist activity in skeletal muscle. With a binding affinity approximately 2-fold higher than first-generation SARMs, S-23 achieves a 5.4-fold selectivity for muscle tissue versus prostate tissue.
Anabolic Capacity
S-23’s high-affinity androgen receptor binding translates directly to enhanced protein synthesis and myofibrillar accretion. In controlled environments, the compound supports progressive lean tissue gain comparable to traditional anabolics while maintaining favourable tissue selectivity. Its potent receptor activation promotes nitrogen retention and satellite cell recruitment—the fundamental mechanisms underlying hypertrophy—making it equally effective during caloric surplus phases as it is renowned for during energy deficit.
This is not magic, its precision biochemistry —
There are no reviews yet.